Related Experiment Video
Updated: May 27, 2026
10:51
The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
Ruthenium(II)/diphosphine/naphthoquinone complexes: synthesis, characterization, anticancer activity and molecular
Analu Rocha Costa1,2, Leticia Pires de Oliveira1, Marcos V Palmeira-Mello1
1Departamento de Química, Universidade Federal de São Carlos, CP 676, CEP 13565-905, São Carlos, SP, Brazil. marcos.palmeira@ufscar.br.
Dalton Transactions (Cambridge, England : 2003)
|May 26, 2026
Summary
New ruthenium complexes show promise as breast cancer treatments. The compound Ru4 demonstrated significant cytotoxicity against triple-negative breast cancer cells, inducing apoptosis and inhibiting colony formation, suggesting a potential new therapeutic strategy.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
- Current treatment options for TNBC are limited, necessitating novel therapeutic strategies.
- Ruthenium complexes offer potential as anticancer agents due to their diverse coordination chemistry and biological activities.
Purpose of the Study:
- To synthesize and characterize novel ruthenium(II) complexes with naphthoquinone ligands for potential breast cancer therapy.
- To evaluate the in vitro cytotoxicity and mechanism of action of these complexes against breast cancer cell lines.
- To identify the most promising compound for further development as a breast cancer therapeutic.
Main Methods:
- Synthesis and characterization of four ruthenium(II) complexes: [Ru(NQ1)(bipy)(dppen)]PF6 (Ru1), [Ru(NQ2)(bipy)(dppen)]PF6 (Ru2), [Ru(NQ1)(bipy)(DPEphos)]PF6 (Ru3), and [Ru(NQ2)(bipy)(DPEphos)]PF6 (Ru4).
- In vitro cytotoxicity assays using MDA-MB-231, MCF-7 (breast cancer), and A549 (lung cancer) cell lines.
- Apoptosis induction, cell cycle analysis, Western blot, cell uptake studies, and DNA-binding assays (including molecular docking).
Main Results:
- All synthesized ruthenium complexes (Ru1-Ru4) exhibited significant in vitro cytotoxicity against tested cancer cell lines, outperforming cisplatin.
- Ru4 demonstrated the highest selectivity index (SI = 25.5) against the triple-negative breast cancer cell line.
- Ru4 induced apoptosis, inhibited colony formation, altered cell cycle progression, and showed intracellular uptake in MDA-MB-231 cells.
- DNA-binding studies confirmed interaction with Ct-DNA via the minor groove.
Conclusions:
- Ruthenium(II) complexes with naphthoquinone ligands represent a promising class of cytotoxic agents against breast cancer.
- The compound [Ru(NQ2)(bipy)(DPEphos)]PF6 (Ru4) is identified as a particularly potent and selective agent against triple-negative breast cancer.
- Ru4's mechanism involves apoptosis induction and DNA interaction, supporting its potential as a novel therapeutic candidate.
